US regulatory status: approved.
biotech · Propionic Acidemia · Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency
SOM Biotech
Moderna Biotech Spain
SOM Biotech drug portfolio — 27 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Barcelona, ES HQ
2009 Founded
14 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Barcelona, ES
- Founded
- 2009
- Employees
- 14
- Programs
- 10
- Drugs
- 27
- Patents
- 0
SOM Biotech pipeline
Portfolio lens on 27 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
SOM Biotech drug portfolio — 27 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
-
Development asset linked to SOM Biotech in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.
- Mechanism
- Histamine H1 receptor antagonist
-
Development asset linked to SOM Biotech in public FDA and regional records.
-
Development asset linked to SOM Biotech in public FDA and regional records.
-
covid-19 mrna vaccine
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in SOM Biotech's portfolio. Molecular target: Spike glycoprotein.
- Target
- Spike glycoprotein
- Mechanism
- Spike glycoprotein vaccine antigen
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to SOM Biotech in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: Histamine H2 receptor.
- Target
- Histamine H2 receptor
- Mechanism
- Histamine H2 receptor antagonist
-
Development asset linked to SOM Biotech in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
ibuprofen
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
influenza vaccine (h1n1)v (split virion, inactivated, adjuvanted)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in SOM Biotech's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
influenza vaccine (live attenuated, nasal)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in SOM Biotech's portfolio.
-
Development asset linked to SOM Biotech in public FDA and regional records.
-
Development asset linked to SOM Biotech in public FDA and regional records.
-
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 3A.
- Target
- 5-hydroxytryptamine receptor 3A
- Mechanism
- Serotonin 3a (5-HT3a) receptor antagonist
-
Development asset linked to SOM Biotech in public FDA and regional records. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Anandamide amidohydrolase inhibitor
-
recombinant respiratory syncytial virus pre-fusion f protein, adjuvanted with as01e
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in SOM Biotech's portfolio. Molecular target: Fusion glycoprotein F0.
- Target
- Fusion glycoprotein F0
- Mechanism
- Fusion glycoprotein F0 vaccine antigen
-
Development asset linked to SOM Biotech in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to SOM Biotech in public FDA and regional records.
-
Development asset linked to SOM Biotech in public FDA and regional records.
-
Development asset linked to SOM Biotech in public FDA and regional records.
-
Development asset linked to SOM Biotech in public FDA and regional records.